We have scotch'd the snake, not kill'd it. She'll close and be herself, whilst our poor malice Remains in danger of her former tooth. —William Shakespeare, in Macbeth , Act II, Scene I

The purpose of this chapter is to address symptoms etiologies that are an abnormality or dysfunction of the nervous system, and are not covered elsewhere in the book.

Neurological symptoms present particular difficulties for those working in pediatric palliative medicine. The evidence base for most symptom interventions derives largely from work done in adults. Historically, adult palliative medicine has largely addressed the needs of patients with cancer, while it is in the large group of children with non-cancer conditions that neurological symptoms occur most commonly. Typically, they are neurodegenerative conditions in which deterioration to death occurs over years or decades, and are characterized by severe neurological symptoms that may be difficult to treat.

The management of neurological symptoms in childhood is complicated both by the inherent intractability of many, and by the lack of a robust evidence base to support effective management. Nevertheless, the broad principles of good palliative care can and should be applied.

General Principles

The most important preparations for providing palliative care to children who may experience neurological symptoms are anticipation, education, and discussion. Informing the child, family, and caretakers about the potential symptoms at an appropriate time can help to reduce anxiety, stress, and unwanted admissions. Ensuring that families have strategies for managing symptoms in a way acceptable to them, even if it is only having the telephone number of someone who can help, will help meet the aims of palliative care. Many families report that honesty and unlimited support are critical elements of the palliative care process. Palliative care approaches should be multidimensional, in the best interest of the child, and rational.

Multidimensional

In considering the impact of neurological symptoms, professionals need to consider not only their physical effects, but also their influence on psychosocial, emotional, and spiritual issues. In focusing on reducing the frequency of seizures, for example, professionals should not lose sight of the need to allow a child to engage meaningfully with his or her family. This can lead to the involvement of a potentially large and extended team with varying but, at times, over-lapping roles ( Box 27-1 ).

BOX 27-1
The Interdisciplinary Team

  • Doctors: from acute, community, and palliative care settings. Those already involved in the management of the child's long-term symptoms and those with the specialist knowledge of management of symptoms experienced toward the end of life.

  • Nursing staff: again they can be involved in each setting; acute hospital, hospice, and in the home and will offer more than physical care but should be specialists in advocating for the child and family when working with the wider team.

  • Therapists and allied health professionals: of varying different specialties; movement and handling, equipment, diet and feeding, communication, learning and education, complementary and alternative medicine treatments.

  • Psychologists: from neuro-psychology and child specialties. They can provide assessment and advice on the child's ability to understand and manage the situation and psychological support to the child, family, and staff involved in the palliative care process.

  • Social workers, bereavement counselors, chaplin, etc.: to offer practical, emotional, and spiritual support to the child and family during the palliative care process and ongoing after the child has died.

  • Key worker: this role helps to access and coordinate appropriate care and is a key point of contact and support for the child and family. Each situation must be assessed when deciding which professional will take on this role. It often falls to nursing staff but in some circumstances another health professional, such as a physiohtherapist, may know the child and family and their needs better.

Always in the best interests of the child

Palliative care is, at its heart, a logical and rational specialty. Professionals should always carefully consider whether a proposed intervention is likely to do more good than harm; whether, on balance, it is in the child's best interest. To be consistent with the principle of multidimensionality above, this clearly means that sometimes professionals will be called on to balance physical benefits with, for example, psychosocial or emotional burdens. In considering the relative weight that should be given to these, it is essential that professionals engage in ongoing dialogue with the family and, where possible the patient. It is rarely possible to make objective judgments about dimensions of experience other than the physical.

Rational

In establishing that a given intervention is in the child's best interest, it is clearly necessary to be aware of the existing evidence. In an age where evidence-based medicine is a professional requirement, it is important that practice is not just based on anecdotes and experience, but also is justified with research. Critical appraisal and clinical reasoning must underpin practice. Systematic reviews or meta-analyses, where they exist, are authoritative sources of such evidence. Individual carefully designed double-blind trials are also powerful evidence. Anecdote and case history, however, are not indicators of effectiveness. They are important signposts to studies that should take place, but should not result in an uncritical change of practice by themselves.

The literature pertaining to non-pharmacological approaches to the management of neurological symptoms is particularly sparse. A rational and logical approach does not, however, mean that practice should be limited only to that rather narrow range of therapeutic options that have been subjected to study in children. It is often necessary to extrapolate from evidence in the adult specialty, or from related disciplines such as acute pain management. Sometimes, professionals working in pediatric palliative care need to be therapeutically creative, using a sound knowledge of pharmacology and therapeutics to develop an approach that, while it may not be fully supported by evidence, is nevertheless rational.

Complementary and alternative medicine (CAM) ap- proaches should be used in conjunction with conventional medicine to aim to provide better symptom control and meet the cultural, spiritual, and psychosocial needs of the child and family. Many neurological symptoms are exacerbated by depression, anxiety, and/or fatigue. There is evidence to suggest these are ameliorated by some CAM approaches, including massage, acupuncture, and transcutaneous electrical stimulation (TENS) can offer some assistance with this. The effectiveness of TENS is unclear but it is well tolerated by most patients. Music therapy and hydrotherapy are naturally enjoyable interventions for children ( Fig. 27-1 ).

Fig. 27-1, Child's depiction of successful family-centered interdisciplinary care of child with neurological symptoms.

Symptoms

For a summary of doses and indications of medications in this chapter, see Table 27-1 .

TABLE 27-1
Doses and Indications for Medications Mentioned in This Chapter
Medication Indication Dosage
Midazolam Status epilepticus and terminal seizure control. Breakthrough anxiety, such as panic attacks. Adjuvant for pain of cerebral irritation. Dyspnea
  • For status epilepticus:

  • By buccal administration,

  • Neonate 300 micrograms/kg as a single dose

  • Child 1-6 mo, 300 micrograms/kg (max. 2.5 mg), repeated once if necessary

  • Child 6 mo-1 yr, 2.5 mg, repeated once if necessary

  • Child 1-5 yrs, 5 mg, repeated once if necessary

  • Child 5-10 yrs, 7.5 mg, repeated once if necessary

  • Child 10-18 yrs, 10 mg, repeated once if necessary

  • For terminal seizure control:

  • By subcutaneous or intravenous infusion over 24 hrs,

  • 50-300 mcg/kg/hour up to maxi. 160 mg

  • For anxiety or dyspnea:

  • Approximately 50% above doses

Diamorphine As for morphine. Useful where large doses need to be dissolved in small volume Relative potency parenteral preparations 3x that of oral morphine.
Phenobarbital Adjuvant in pain of cerebral irritation. Control of terminal seizures. Sedation
  • By mouth:

  • Neonates, loading dose by slow intravenous injection, then 2.5-5 mg/kg by mouth once a day

  • Child 1 mo-12 yrs, 1-1.5 mg/kg twice a day, increased by 2 mg/kg daily as required (usual maintenance dose 2.5-4 mg/kg once or twice a day)

  • Child 12-18 yrs, 60-180 mg once a day.

Diazepam Short-term anxiety relief. Relief of muscle spasm. Treatment of status epilepticus
  • Short-term anxiety relief:

  • By mouth:

  • Child 2-12 yrs, 2-3 mg three times a day

  • Child 12-18 yrs, 2-10 mg three times a day

  • Relief of muscle spasm:

  • By mouth:

  • Child 1-12 mo, initially 250 mcg/kg twice a day

  • Child 1-5 yrs, initially 2.5 mg twice a day

  • Child 5-12 yrs, initially 5 mg twice a day

  • Child 12-18 yrs, initially 10 mg twice a day, maxi.

  • Total daily dose 40 mg

  • Status epilepticus:

  • By intravenous injection over 3-5 min:

  • Neonate, 300-400 mcg/kg repeated after 10 min if necessary

  • Child 1 mo-12 yrs, 300-400 mcg/kg repeated after 10 min if necessary

  • Child 12-18 yrs, 10-20 mg repeated after 10 min if necessary

  • By rectum:

  • Neonate, 1.25-2.5 mg repeated after 10 min if necessary

  • Child 1 mo-2 yrs, 5 mg repeated after 10 min if necessary

  • Child 2-12 yrs, 5-10 mg repeated after 10 min if necessary

  • Child 12-18 yrs, 10 mg repeated after 10 min if necessary

Levomepromazine Antiemetic where cause is unclear, or where probably multifactorial. Secondary effects include sedation and analgesia
  • Antiemetic:

  • By mouth:

  • Child 2-12 yrs, starting dose 0.1-1 mg/kg, max 25 mg

  • Child greater than 12 yrs, 6.25-25 mg by mouth once or twice daily

  • By continuous intravenous or subcutaneous infusion over 24 hrs:

  • Child 1 mo-12 yrs, 100-400 mcg/kg over 24 hrsChild greater than 12-18 yrs, 5-25 mg over 24 hrs

  • For sedation:

  • By subcutaneous infusion over 24 hrs:

  • Child 1 yr-12 yrs, 0.35-3 mg/kg over 24 hrs

  • Child over 12-18 yrs, 12.5-200 mg over 24 hrs

  • Analgesic: May be of benefit in a very distressed patient with severe pain unresponsive to other measures

  • Stat dose 0.5 mg/kg by mouth or subcutaneously. Titrate dose according to response; usual maximum daily dose in adult 100 mg subcutaneous or 200 mg by mouth

Fentanyl Severe pain (synthetic opioid analgesic), particularly as rotation from morphine or if patch formulation desirable
  • By transmucosal application (lozenge with oromucosal applicator):

  • Child 2-18 yrs, 15-20 mcg/kg as a single dose, max. dose 400 mcg

  • By transdermal patch:

  • Based on oral morphine dose-equivalent Product monogram,

  • Oral morphine 60-134 mg = 25 mcg/h patch of fentanyl

  • Oral morphine 180-224 mg = 50 mcg/h patch of fentanyl

  • Oral morphine 27-314 mg = 75 mcg/h patch of fentanyl

Hydromorphone Severe pain (opioid analgesic) especially if diamorphine unavailable and solubility is an issue
  • By mouth:

  • Child 12-18 yrs, initially 1.3 mg every 4 hrs, increasing as required

Tizanidine Muscle spasm
  • By mouth:

  • Adult dose, initially 2 mg increasing in increments of 2 mg at intervals of 3 to 4 days. Give total daily dose in divided doses up to 3-4 times daily. Usual total daily dose 24 mg. Maximum total daily dose 36 mg

Baclofen Chronic severe spasticity of voluntary muscle
  • By mouth:

  • Initially, Child 1-10 yrs 0.75-2 mg/kg daily or 2.5 mg 4 times daily.

  • Increased gradually to maintenance:

  • Child 1-2 yrs, 10-20 mg daily in divided doses

  • Child 2-6 yrs, 20-30 mg daily in divided doses

  • Child 6-10 yrs, 30-60 mg in divided doses

Melatonin Sleep disturbance caused by disruption of circadian rhythm (not anxiolytic)
  • By mouth:

  • Dose unknown, initially 2-3 mg, increasing every 1-2 wk dependent on effectiveness up to maximum 10 mg (higher doses have been used)

Seizures

Management of seizures outside the terminal phase is beyond the scope of this chapter. The palliative care professional should continue to liaise carefully with colleagues in neurology, even as death approaches. Potentially, this can achieve several important objectives:

  • Rationalization of anticonvulsant medications

Children with life-limiting conditions in ACT categories III and IV ( Table 27-2 ), which are often chronic neurological conditions, are likely to have seizures that have been difficult to control for some time. The result is typically that, at the time it is clear a palliative phase has been entered, children are on a large number of different anticonvulsants.

TABLE 27-2
Life-Limiting Conditions
Adapted from Categories of life-timing and life-threatening conditions. Available from www.act.org.uk.
The original ACT/RCPCH categories 25

Category Definition Example conditions Characteristic
I Life-threatening conditions for which curative treatment may be feasible but can fail. Palliative care may be necessary during phases of prognostic uncertainty and when treatment fails. Cancer, cardiac anomalies Possible cure
II Conditions in which there may be long phases of intensive treatment aimed at prolonging life and allowing participation in normal childhood activities, but premature death is still possible Cystic fibrosis, Muscular dystrophy, HIV/AIDS with antiretroviral treatment Normal phase
III Progressive conditions without curative treatment options, in which treatment is exclusively palliative and may commonly extend over many years Batten's disease, Mucopolysaccharidosis, HIV/AIDS without antiretroviral treatment Relentless progression
IV Conditions with severe neurological disability, which may cause weakness and susceptibility to health complications, and may deteriorate unpredictably, but are not considered progressive Severe cerebral palsy Unpredictable

The long-term management of seizures requires a neurologist to balance carefully immediate benefit with long-term side effects. In the palliative phase, such a balance may no longer be necessary. Discussion with neurology colleagues may allow:

  • Discontinuation of some anticonvulsants,

  • Reduction in the number of anticonvulsants,

  • Substitution of specific anticonvulsants with broader range ones with additional desirable benefits such as anxiolysis or activity against neuropathic pain.

Management of breakthrough seizures usually requires a parenteral approach. This presents a conflict with one of the aims of palliative care, which is to offer the family the choice of locations, typically home, hospital, or hospice, for death to occur. The intravenous and subcutaneous routes may not be appropriate, because they are not usually available except to professionals who may not be immediately on hand.

The solution to this is to use the buccal route. Small volumes of water soluble drugs such as midazolam and diamorphine can be administered between the cheek and the gum. They are absorbed rapidly through the oral mucosa, effectively providing an alternative parenteral route without needles. This is increasingly used for management of breakthrough seizures in neurology and is ideally suited to their management in the terminal phase.

  • Management of terminal seizures

The two mainstays of seizure management in the terminal stages are phenobarbital and midazolam. Both may be given as continuous subcutaneous infusion, though phenobarbital must be given separately from other medications. The decision as to which of these should be first-line use is largely up to the clinician; there is little evidence to suggest which is likely to be more effective, and it may depend on the individual circumstances and patient.

  • Phenobarbital

Phenobarbital is rarely used in seizure disorders because of the risk of adverse effect in long-term use. In the palliative phase, however, where these are unlikely to be a significant consideration, it has a number of potential advantages over many other anticonvulsants, though not all are proved. It is anxiolytic, rather than simply sedative, effective against cerebral irritation; is sedating it may have some activity against neuropathic pain. It can also be given orally or through a gastrostomy tube.

It does, however, also have some disadvantages:

It induces its own metabolism, so the dose may need to be kept under review; and its long half-life means it cannot easily be titrated against its effect, particularly if given orally.

  • Midazolam

Midazolam is a short-acting benzodiazepine. It is often used by neurologists for breakthrough seizures, but rarely for background control because of its short half-life. In the palliative phase, Midazolam is usually given by continuous subcutaneous infusion although there is no reason in principle why it should not also be given intravenously. It can be mixed with other medications in the same syringe driver, including diamorphine, morphine, levomepromazine, and other medications commonly used in the final days of life. It is easy to titrate against symptoms due to its short half-life; powerfully anxiolytic, amnestic and sedating; and has a broad range of anticonvulsant activity. Midazolam is widely used in pediatric palliative care, so it has reasonable clinical experience and evidence base. Also, it is highly soluble so can be given by buccal route.

Midazolam's disadvantages are that paradoxical agitation can occur in some children and its short half-life makes it inappropriate for background control of seizures except by parenteral infusion. The drug can cause confusion; and in cognitively aware children, loss of memory may be a disadvantage, particularly if it impairs family relationships.

The decision as to which is the better first-line approach will depend largely on individual circumstances. For a child who has otherwise no need for parenteral access, phenobarbital given orally may be preferable. For a child needing benzodiazepines for other reasons, midazolam may be the logical choice. For many children, adequate control of seizures in the terminal phase will in practice require both drugs to be given parenterally as the swallowing reflex becomes lost.

Breakthrough seizures

Before embarking on management of breakthrough seizures, it is important to discuss with the child's family what their expectations are. Most families have lived with a child with complex seizure disorder for many years and will be able to fully engage in a discussion about what can and cannot be achieved in the way of control in the final days and weeks of life.

It is important to acknowledge that seizures are more unpleasant and frightening for those observing them than they are for the child who experiences them. If seizures do not appear to distress the child, then vigorous attempts to abolish them may result in replacing acceptable seizures with unacceptable adverse effects. For families used to a child who has many seizures a day, reducing them to only one or two seizures a day may be an acceptable outcome.

It is also important to acknowledge that complete control of seizures may simply not be possible. If complete absence of seizures can only be achieved by means of anesthesia and ventilation, from which there is no realistic prospect of the child's recovering, it is a price too high for the child to pay. This needs to be explored with the family at the time management of terminal seizures is initiated.

It is usual for children with complex seizure disorders to have a detailed seizure protocol that has been agreed between neurologist and family. It is important that the palliative care pediatrician be aware of this protocol, and that he or she work carefully with the neurology team and the family themselves before suggesting any modification. This protocol should be accessible to all those involved with the child and identify what is normal for that child, when a seizure has become prolonged and requires medication, and at what stage and to what level further help should be sought if seizure activity continues.

One common medication used for treatment of breakthrough seizures, when indicated, is diazepam, which may be given by the rectal route. The metabolites of diazepam are active and long-lasting, but this is rarely a problem in children. Children prefer to avoid the rectal route where possible, as it is uncomfortable and undignified. Nevertheless, it is certainly preferred to a needle by most and may be the most accessible in the midst of a seizure. The rectal route is contraindicated in neutropenia or marked thrombocytopenia.

Non-pharmacological management

Even in the terminal phase, immediate nursing interventions aimed at making the child comfortable are important. These would include correct positioning of the child, and oxygen if indicated. The timing of anti-seizure medications should be carefully defined ahead of time in a clear seizure protocol, that takes account of the needs and priorities of the individual child and family. Short, self-limiting seizures will commonly need no such intervention.

The mainstay of non-pharmacological management of seizures is to avoid over-handling. Intractable seizures are likely to be exacerbated by stimulation and, as most therapeutic interventions entail touch and some stimulation of the senses, involvement of therapists is likely to be in managing co-existing symptoms such as pain and muscle spasms. If triggering seizures is perceived by the child, family, and care team to be a small burden whilst the benefit gained from a pleasurable intervention such as music therapy or massage is more significant, then such therapies should be offered. The therapist should, however, be cautiously aware and constantly re-evaluate.

Because many children who experience seizures near the end of life have chronic neurological conditions, it is likely that they will also have other symptoms that may benefit from therapeutic involvement. Although not directly treating the seizures, effective tone-reducing positioning may ensure that the child is more comfortable and functional between seizures. Positioning aids such as sleep systems and soft splinting should not forcibly restrain abnormal movement patterns but should encourage comfort positions and allow function by supporting where required. For example, a child with trunk and lower limb hypertonia, when positioned in supine is likely to extend. By positioning the child on his or her side in flexion or in supine but with appropriate soft positioning aids to encourage trunk, hip, and knee flexion, even if a tonic-clonic seizure occurs, the child is not going to injure himself or herself but once resolved they will recover back into a tone-minimizing and, by the same token, comfortable position.

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here